Project Grant R01HL183374
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $806K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Washington $1,233,682 on May 1, 2026, for research bridging basic and clinical science to prevent cardiovascular disease in diabetes under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses residual cardiovascular disease risk in youth and adults with type 1 and type 2 diabetes despite standard LDL-cholesterol-lowering interventions. The project investigates whether increased hepatic...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $188,786 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a K23 career development award focused on investigating sphingolipids as a cardiovascular disease risk factor in patients with kidney disease. The award funds career development and research training for an assistant professor in nephrology at the University of Washington to transition to an independent...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $881,454 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish relationships between poor access to healthy food, inadequate clinical care, and hypertension progression in youth, and to identify strategies to overcome these barriers. The award supports research under the Study of the Epidemiology of Pediatric Hypertension (SUPERHERO) Registry, a longitudinal...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $777,814 on August 15, 2026, to develop computational methods for enhanced clinical use of single-cell data under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of novel analytical frameworks to extract clinically actionable biomarkers from single-cell data generated by flow cytometry and other clinical technologies. The project addresses three gaps in current...
- The National Heart, Lung, and Blood Institute awarded the University of Denver $169,638 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate neighborhood food access as a predictor of cardiovascular disease risk in early childhood. The project applies a prospective mechanistic approach to test whether limited neighborhood food access associates with obesogenic food-related behaviors and higher cardiovascular disease risk in early childhood. The...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $874,014 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the relationship between gut microbiota, metabolite composition, and salt sensitivity of blood pressure. The research quantifies salt sensitivity of blood pressure as the change in 24-hour ambulatory mean arterial pressure from one week of high-salt to one week of low-salt diet in 50 adult subjects...
- The National Heart, Lung and Blood Institute awarded the University of Washington $233,250 under CFDA 93.837 (Cardiovascular Diseases Research) on June 18, 2026, to conduct AI-guided structural biology research on CAV1.2, an L-type calcium channel critical to cardiac contraction and excitation-coupling in the heart. The research will develop an artificial-intelligence-informed platform for structural biology of the CAV1.2 C-terminal domain (CTD), a 571-residue segment whose three-dimensional...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington $2,647,494 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental models of myosin variants that determine how single amino acid variants affect myosin structure and function across multiple scales. The project integrates molecular and Brownian dynamics simulations of the chemo-mechanical cycle of β-myosin, generated from human crystal and...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $131,880 on July 10, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to support patient-oriented translational research mentoring focused on understanding host response heterogeneity in community-acquired pneumonia and pneumonia-related organ failure. The award funds a mid-career mentoring program led by an associate professor of medicine and co-director of the Sepsis Center of Research Excellence at...